Filing Details

Accession Number:
0001209191-18-020565
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-19 16:17:31
Reporting Period:
2018-03-15
Accepted Time:
2018-03-19 16:17:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1368148 Athersys Inc / New ATHX Pharmaceutical Preparations (2834) 204864095
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1402610 J John Harrington 3201 Carnegie Avenue
Cleveland OH 44115-2634
Exec Vice Pres And Cso Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-03-15 7,500 $1.86 635,032 No 4 S Direct
Common Stock Disposition 2018-03-16 7,500 $1.83 627,532 No 4 S Direct
Common Stock Disposition 2018-03-17 7,529 $1.86 620,003 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 F Direct
Footnotes
  1. Shares sold pursuant to a predefined Rule 10b5-1 trading plan for tax and planning purposes.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.830 to $1.940, inclusive, in accordance with a previously established Rule 10b5-1 predefined trading plan enacted for tax and planning purposes.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.790 to $1.860, inclusive, in accordance with a previously established Rule 10b5-1 predefined trading plan enacted for tax and planning purposes.
  4. Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the minimum tax withholding obligation.
  5. Securities beneficially owned are comprised of: (1) 394,873 shares of common stock owned and (2) unvested restricted stock units aggregating 225,130 related to annual awards, which vest quarterly over a four-year period from grant date.